Development and validation of the FAAP model for prognostic stratification in HCC patients treated with TACE, sintilimab plus bevacizumab: a multicenter study
The FAAP scoring system effectively predicted survival outcomes in HCC patients receiving TACE-sintilimab-bevacizumab therapy, which suggests its clinical utility for prognostic prediction. Further large prospective studies are required for external validation.
Authors
- Dongbo Chen (ORCID: https://orcid.org/0009-0007-5594-8914)
- Liying Ren (ORCID: https://orcid.org/0000-0003-3624-5483)
- Jie Gao (ORCID: https://orcid.org/0000-0003-1075-3631)
- Shaoping She (ORCID: https://orcid.org/0000-0001-9796-9253)
- Weijia Liao (ORCID: https://orcid.org/0000-0002-8906-8612)
- Xue Zhang (ORCID: https://orcid.org/0000-0003-4279-899X)
- Cong Xu (ORCID: https://orcid.org/0000-0002-9571-326X)
- Hongsong Chen (ORCID: https://orcid.org/0000-0002-2084-8653)
- Yuchen Zhou (ORCID: https://orcid.org/0000-0002-9482-5489)
- Ran Fei (ORCID: https://orcid.org/0000-0002-8484-9516)
- Shuo Mu (ORCID: https://orcid.org/0009-0004-7810-0690)
Institutions
- Guilin Medical University (CN)
- Peking University (CN)
- Nanfang Hospital (CN)
- Peking University People's Hospital (CN)
- TCM-Intigrated Cancer Center of Southern Medical University (CN)
- Peking University Third Hospital (CN)
- Southern Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-11-25
- DOI
- https://doi.org/10.3389/fimmu.2025.1692632
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Peking University
- Beijing Nova Program
- Fundamental Research Funds for the Central Universities